- Talks with Senegal, Tunisia “quite advanced”
- France will give financial support to project
- Hubs could eventually make non-COVID vaccines
GENEVA, June 29 (Reuters) – Plans for Africa’s first independent COVID-19 vaccine production hubs could revolutionise the global vaccine industry but will depend on the willingness of pharmaceutical companies to share their technology, the World Health Organization said on Tuesday.
The Geneva-based health agency said last week it is setting up a hub with South Africa to give poorer countries the tools to produce their own COVID-19 vaccines using mRNA technology currently used in Moderna and Pfizer‘s COVID shots. read more
WHO’s Agnès Buzyn, the WHO head’s envoy for multilateral affairs, said that several other African and Asian countries had also applied and discussions with Senegal and Tunisia were “quite advanced”.
“You can call it revolutionary in that it has never been envisaged before with this speed and this ambition,” said Buzyn. “The key question is: will those in the industry with the most advanced technology accept to transfer it.”
WHO talks are ongoing with Pfizer and Moderna, although it is not clear whether they will accept to share their technology which might have the potential to undermine future sales. While the latter has said it will not enforce patents on its vaccine during the pandemic, some health experts say that what is needed more urgently to expand manufacturing is know-how.
But even without any help from pharmaceutical giants, start-ups could fill the gap, even if their mRNA technology was “less mature”, Buzyn said.
This would push production back beyond the current target of end-2022, she said.
Sana de Courcelles, a French health diplomat leading its international response to COVID-19, said France would support the South African hub politically as well as financially, without fixing a sum.
“It is time to share – to share doses but also to share the technology, the knowledge and to share a sense of collective moral duty,” she said.
South African company, Aspen Pharmacare, is already producing shots of the J&J vaccine locally.
Steps are being planned to ensure that new African production hubs have a regional market where they can sell non-COVID vaccines in future, said Marie-Paule Kieny from the Medicines Patent Pool which is preparing the contracts for the South Africa centre.
“If you expect a new manufacturer in South Africa to make vaccines less expensive than a big Indian producer then you are dreaming,” she said. “We cannot just construct something that works only for the pandemic.”
Reporting by Emma Farge
Editing by Raissa Kasolowsky
Our Standards: The Thomson Reuters Trust Principles.